- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05925023
Sirolimus in the Treatment of Refractory/Relapsed wAIHA
August 16, 2023 updated by: Chen Miao, Peking Union Medical College Hospital
Sirolimus in the Treatment of Refractory/Relapsed Warm Autoimmune Hemolytic Anemia (AIHA): a Phase 2 Prospective Trial
Autoimmune hemolytic anemia (AIHA) is a rare and heterogeneous disorder characterized by the destruction of red blood cells through warm or cold antibodies.
Glucocorticoid (combined with rituximab) is the first-line treatment.
However, the recurrence rate is very high and some patients may not respond to steroids.
Second-line therapies include cyclosporine A (CsA), cyclophosphamide, rituximab, azathioprine, and even splenectomy.
Our previous study of sirolimus in refractory/relapsed AIHA and ES found an effective rate of 80%.
Therefore, the investigators plan to explore the efficacy and safety of sirolimus in the treatment of refractory/relapsed wAIHA.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Based on the optimal autoantibody-RBC reactivity temperatures, AIHA is classified into warm type, cold type, and mixed type.
AIHA can be further classified into primary or secondary in nature.
Glucocorticoid (combined with rituximab) is the first-line treatment.
However, the recurrence rate is very high and some patients may not respond to steroids.
Second-line therapies include cyclosporine A (CsA), cyclophosphamide, rituximab, azathioprine, and even splenectomy.
The refractory/relapsed wAIHA patients have increased cardiovascular events, increased opportunities for infections, decreased quality of life, and even death.
A prospective multi-institutional trial in autoimmune cytopenia found that 8 of 10 patients with AIHA and Evans syndrome respond to sirolimus.
Our previous study of sirolimus in refractory/relapsed AIHA and ES also found an effective rate of approximately 80%.
Since sirolimus is cheap and accessible, our findings may reduce the economic burden of patients and be a guide on the selection of second-line treatment drugs in refractory/relapsed wAIHA and Evans syndrome.
Study Type
Interventional
Enrollment (Estimated)
22
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100730
- Recruiting
- Peking Union Medical College Hospital
-
Contact:
- Miao Chen
- Phone Number: +86 13520112578
- Email: chenm@pumch.cn
-
Contact:
- Bing Han
- Phone Number: +86 69155028
- Email: hanbingpumch@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age ≥18 years old.
- Diagnosed as primary warm autoimmune hemolytic anemia or Evans syndrome (primary or secondary). There is no treatment indication of other systemic involvement in the original disease if secondary.
- No response to glucocorticoid therapy or recurrence.
- Baseline liver (ALT, AST) was less than 2 times the normal value.
- No active infection; Not pregnant or breastfeeding.
- Agree to sign the consent form.
Exclusion Criteria:
- Patients with connective tissue disease or other organs involvement
- Infection or bleeding that cannot be controlled by standard treatment.
- Active HIV, HCV or HBV infection or cirrhosis or portal hypertension.
- Progressed uncontrolled malignant tumors and lymphoma
- Cirrhosis or portal hypertension.
- Pregnant or breastfeeding.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sirolimus on refractory/relapsed wAIHA
A prospective research of the sirolimus efficiency on refractory/relapsed primary wAIHA patients.
Sirolimus dosage: 1-3 mg/d with plasma concentration 4-15ng/mL.
Medication time should last at least 6 months.
After reaching the optimal response, responders continue to use sirolimus for 1 year, and then gradually reduce the dosage.
|
Oral administration, 1-3 mg/d, sirolimus plasma concentration: 4-15 ng/mL
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall response rate (ORR)
Time Frame: 12 months
|
ORR defined as the proportion of patients who met the criteria of either complete response (CR) or partial response (PR).
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete response rate (CRR
Time Frame: 12 months
|
CRR defined as the proportion of patients who met the criteria of complete response.
|
12 months
|
Adverse events
Time Frame: 12 months
|
Safety analyses include assessments of the incidence and severity of adverse events; all adverse events that occurred or worsened during the treatment period will be reported, as well as adverse events that occurred later but are considered by the investigator to be related to the trial drug.
|
12 months
|
Relapse rate
Time Frame: 12 months
|
Relapse rate defined as the proportion of patients whose response shift from PR or CR to no response (NR).
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Barcellini W, Fattizzo B, Zaninoni A, Radice T, Nichele I, Di Bona E, Lunghi M, Tassinari C, Alfinito F, Ferrari A, Leporace AP, Niscola P, Carpenedo M, Boschetti C, Revelli N, Villa MA, Consonni D, Scaramucci L, De Fabritiis P, Tagariello G, Gaidano G, Rodeghiero F, Cortelezzi A, Zanella A. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. Blood. 2014 Nov 6;124(19):2930-6. doi: 10.1182/blood-2014-06-583021. Epub 2014 Sep 16.
- Birgens H, Frederiksen H, Hasselbalch HC, Rasmussen IH, Nielsen OJ, Kjeldsen L, Larsen H, Mourits-Andersen T, Plesner T, Ronnov-Jessen D, Vestergaard H, Klausen TW, Schollkopf C. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. Br J Haematol. 2013 Nov;163(3):393-9. doi: 10.1111/bjh.12541. Epub 2013 Aug 24.
- Jager U, Barcellini W, Broome CM, Gertz MA, Hill A, Hill QA, Jilma B, Kuter DJ, Michel M, Montillo M, Roth A, Zeerleder SS, Berentsen S. Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting. Blood Rev. 2020 May;41:100648. doi: 10.1016/j.blre.2019.100648. Epub 2019 Dec 5.
- Bass GF, Tuscano ET, Tuscano JM. Diagnosis and classification of autoimmune hemolytic anemia. Autoimmun Rev. 2014 Apr-May;13(4-5):560-4. doi: 10.1016/j.autrev.2013.11.010. Epub 2014 Jan 11.
- Hill QA, Stamps R, Massey E, Grainger JD, Provan D, Hill A; British Society for Haematology. The diagnosis and management of primary autoimmune haemolytic anaemia. Br J Haematol. 2017 Feb;176(3):395-411. doi: 10.1111/bjh.14478. Epub 2016 Dec 22. No abstract available.
- Barcellini W, Fattizzo B. How I treat warm autoimmune hemolytic anemia. Blood. 2021 Mar 11;137(10):1283-1294. doi: 10.1182/blood.2019003808. Erratum In: Blood. 2023 Jan 26;141(4):438-439.
- Bride KL, Vincent T, Smith-Whitley K, Lambert MP, Bleesing JJ, Seif AE, Manno CS, Casper J, Grupp SA, Teachey DT. Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood. 2016 Jan 7;127(1):17-28. doi: 10.1182/blood-2015-07-657981. Epub 2015 Oct 26.
- Li H, Ji J, Du Y, Huang Y, Gu H, Chen M, Wu R, Han B. Sirolimus is effective for primary relapsed/refractory autoimmune cytopenia: a multicenter study. Exp Hematol. 2020 Sep;89:87-95. doi: 10.1016/j.exphem.2020.08.001. Epub 2020 Aug 6.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 24, 2023
Primary Completion (Estimated)
December 1, 2024
Study Completion (Estimated)
December 1, 2025
Study Registration Dates
First Submitted
June 21, 2023
First Submitted That Met QC Criteria
June 21, 2023
First Posted (Actual)
June 29, 2023
Study Record Updates
Last Update Posted (Actual)
August 21, 2023
Last Update Submitted That Met QC Criteria
August 16, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Autoimmune Diseases
- Hematologic Diseases
- Anemia
- Hemolysis
- Anemia, Hemolytic
- Anemia, Hemolytic, Autoimmune
- Physiological Effects of Drugs
- Anti-Infective Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antifungal Agents
- Sirolimus
Other Study ID Numbers
- Sirolimus-1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Warm Autoimmune Hemolytic Anemia
-
SanofiActive, not recruitingWarm Autoimmune Hemolytic Anemia (wAIHA)United States, Austria, China, Denmark, Germany, Hungary, Italy, Spain, United Kingdom
-
SanofiTerminatedWarm Autoimmune Hemolytic Anemia (wAIHA)United Kingdom, Belgium, Netherlands, France, United States, Germany, Hungary, Italy
-
Novartis PharmaceuticalsRecruitingWarm Autoimmune Hemolytic Anemia (wAIHA)China, Japan, Spain, Singapore, France, Germany, Taiwan, United States, Italy, India, Malaysia, Argentina, Hungary, Israel, Australia, Thailand, United Kingdom, Romania
-
Annexon, Inc.CompletedWarm Autoimmune Hemolytic Anemia (wAIHA)United States
-
Eugene NikitinUnknownAIHA - Warm Autoimmune Hemolytic AnemiaRussian Federation
-
Incyte CorporationActive, not recruitingWarm Autoimmune Hemolytic Anemia (wAIHA)Spain, United States, Austria, Belgium, Canada, France, Germany, Israel, Italy, Japan, Netherlands, Poland, United Kingdom
-
Alexion PharmaceuticalsWithdrawnWarm Autoimmune Hemolytic AnemiaUnited States
-
Alexion PharmaceuticalsTerminatedWarm Autoimmune Hemolytic AnemiaUnited States, Jordan
-
Chen MiaoRecruiting
-
Immunovant Sciences GmbHTerminatedWarm Autoimmune Hemolytic AnemiaUnited States, Korea, Republic of, Israel, United Kingdom, Spain, Thailand
Clinical Trials on Sirolimus
-
Aadi Bioscience, Inc.Approved for marketingTSC1 | TSC2 | PEComa, Malignant | mTOR Pathway Abberation
-
Johns Hopkins UniversityMacuSight, Inc.CompletedPanuveitis | Uveitis | Posterior Uveitis | Intermediate UveitisUnited States
-
Aadi Bioscience, Inc.CompletedHigh Grade Recurrent Glioma and Newly Diagnosed GlioblastomaUnited States
-
Stefan Schieke MDWithdrawnCutaneous T-cell Lymphoma (CTCL)United States
-
Brigham and Women's HospitalNational Heart, Lung, and Blood Institute (NHLBI)CompletedLymphangioleiomyomatosisUnited States
-
Xijing HospitalAir Force Military Medical University, China; Shanghai MicroPort Medical (Group)... and other collaboratorsUnknown
-
The University of Texas Health Science Center,...Society for Pediatric DermatologyCompletedTuberous Sclerosis | Neurofibromatoses | Neurofibroma | AngiofibromaUnited States
-
Paul S Teirstein, MDCordis CorporationCompletedCoronary Artery Disease | Coronary Thrombosis | Coronary RestenosisUnited States
-
Meril Life Sciences Pvt. Ltd.Lifecare Institute of Medical Sciences and Research Ahmedabad Gujarat IndiaCompleted
-
Shanghai Jiao Tong University School of MedicineUnknownCoronary Artery DiseaseChina